Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
56.6M
-
Number of holders
-
76
-
Total 13F shares, excl. options
-
39.9M
-
Shares change
-
+1.2M
-
Total reported value, excl. options
-
$667M
-
Value change
-
+$24.3M
-
Put/Call ratio
-
0.16
-
Number of buys
-
45
-
Number of sells
-
-28
-
Price
-
$16.72
Significant Holders of Design Therapeutics, Inc. - Common Stock, par value $0.0001 per share (DSGN) as of Q3 2022
92 filings reported holding DSGN - Design Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q3 2022.
Design Therapeutics, Inc. - Common Stock, par value $0.0001 per share (DSGN) has 76 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 39.9M shares
of 56.6M outstanding shares and own 70.52% of the company stock.
Largest 10 shareholders include SR ONE CAPITAL MANAGEMENT, LP (5.63M shares), Cormorant Asset Management, LP (5M shares), BlackRock Inc. (3.6M shares), Logos Global Management LP (2.8M shares), RA CAPITAL MANAGEMENT, L.P. (2.77M shares), EcoR1 Capital, LLC (2.52M shares), CITADEL ADVISORS LLC (2.42M shares), Avoro Capital Advisors LLC (2.22M shares), VANGUARD GROUP INC (1.55M shares), and JANUS HENDERSON GROUP PLC (1.5M shares).
This table shows the top 76 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.